Pfizer Relpax is seventh triptan
This article was originally published in Pharmaceutical Approvals Monthly
Pfizer's migraine therapy Relpax (eletriptan) clears FDA Dec. 26, becoming the seventh approved triptan. Approval was delayed while Pfizer conducted FDA-requested cardiovascular safety trials addressing safety of higher doses. FDA approved 20 mg and 40 mg single doses, but not 80 mg. The larger dose had higher response rates in five of six efficacy studies, but with more adverse events. Labeling allows for a maximum of two daily doses not to exceed 80 mg. Pfizer will launch Relpax during the first quarte
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”